Date: 2013-05-02
Type of information: Licensing agreement
Compound: cFMS cancer program
Company: Redx Pharma (UK) Pharmascience (Canada)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: Pharmascience program is focused on small molecules that inhibit a receptor in the body called CSF-1R or cFMS which plays an important role in the immune response to cancer. The receptor influences the way that the body\'s immune system interacts with cancer cells in tumours. It also affects how quickly cancer spreads to other parts of the body, particularly to bones. cFMS inhibitors may help prevent the innate immune system from \"tolerating\" cancer by keeping macrophages from converting to their pro-inflammatory, but tumour-tolerant state. By inhibiting this key element of cancer\'s ability to hide from the immune system, these compounds may help the body\'s immune system to better recognize and kill cancers. The compounds may also reduce the ability of metastatic cancer cells from being deposited in the bones of cancer patients. Bone metastases are a serious and painful complication of several major cancers including breast and prostate cancer.
Disease:
Details: * On May 2, 2013, Redx Pharma and Pharmascience have enter into license agreement for cFMS cancer program. Pharmascience program is focused on small molecules that inhibit a receptor in the body called CSF-1R or cFMS which plays an important role in the immune response to cancer. The receptor influences the way that the body\'s immune system interacts with cancer cells in tumours. It also affects how quickly cancer spreads to other parts of the body, particularly to bones. The license agreement allows Liverpool-based Redx to pursue research and development and commercialization of the Pharmascience program in oncology. The program is currently at the lead optimization stage.
Financial terms: Financial terms were not disclosed.
Latest news:
